References
- Raza A., Gezer S., Mundel S., Gao X. Z., Alvi S., Borok R, Rifkin S., Iftikhar A., Shetty V., Parcharidou A. Apoptosis in bone marrow samples involving strormal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86: 268–276
- Greenberg P., Cox C., LeBeau M., Fenaux P., Morel P., Sanz G., Sanz M., Vallespi T., Hamblin T., Oscier D., Ohyashiki K., Toyama K., Aul C., Mufti G., Bennett J. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079–2088
- Kantarjian H. M., Beran M., Ellis A., Zwelling L., O'Brien S., Cazenave L., Koller C., Rios M. B., Plunkett W., Keating M. J. Phase I study of topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146–1151
- Rowinsky E. K., Adjei A., Donehower R. C., Gore S. D., Jones R. J., Burke P. J., Cheng Y. C., Grochow L. B., Kaufmann S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology 1994; 12: 2193–2203
- Seiter K., Feldman E. J., Halicka H. D., Traganos F., Darzynkiewicz Z., Lake D., Ahmed T. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of Clinical Oncology 1997; 15: 44–51
- Lynch T. J., Jr., Kalish L., Strauss G., Elias A., Skarin A., Shulman L. N., Posner M., Frei E. 3rd Phase II study of topotecan in metastatic non-small-cell lung cancer. Journal of Clinical Oncology 1994; 12: 347–352
- Creemers G. J., Bolis G., Gore M., Scarfone G., Lacave A. J., Guastalla J. P., Despax R., Favalli G., Kreenberg R., Van Belle S., Hudson I., Verweij J., Bokkel Ten, Huinink W. W. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase n study. Journal of Clinical Oncology 1996; 14: 3056–3061
- Beran M., Kantarjian H., O'Brien S., Koller C., al-Bitar M., Arbuck S., Pierce S., Moore M., Abbruzzese J. L., Andreeff M., Keating M., Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473–2479
- Beran M., Estey E., O'Brien S., Cortes J., Koller C. A., Giles R, Kornblau S., Andreeff M., Vey N., Pierce S. R., Hayes K., Wong G.C., Keating M., Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Journal of Clinical Oncology 1999; 17: 2819–2830
- National Cancer Institute Common Toxicity Criteria, Version 2.0, April 30, 1999
- Rowinsky E. R., Kaufmann S. H., Baker S. D., Miller C. B., Sartorius S. E., Bowling M. K., Chen T.-L., Donehower R. C., Gore S. D. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia. Clinical Cancer Research 1996; 2: 1921–1930